Celularity (NASDAQ:CELU) Stock Price Down 3.6%

Shares of Celularity Inc. (NASDAQ:CELU) dropped 3.6% on Tuesday . The stock traded as low as $2.59 and last traded at $2.64. Approximately 19,462 shares changed hands during trading, a decline of 83% from the average daily volume of 112,964 shares. The stock had previously closed at $2.74.

Celularity Trading Down 5.8 %

The firm’s 50 day simple moving average is $2.96 and its two-hundred day simple moving average is $3.56.

Hedge Funds Weigh In On Celularity

A hedge fund recently bought a new stake in Celularity stock. Keynote Financial Services LLC acquired a new stake in shares of Celularity Inc. (NASDAQ:CELU) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 15,566 shares of the company’s stock, valued at approximately $81,000. Keynote Financial Services LLC owned 0.08% of Celularity at the end of the most recent reporting period. 19.02% of the stock is owned by institutional investors and hedge funds.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.